key: cord-0908169-l0rhu9nf
authors: Foster, Brian; Liaqat, Adnan; Chib, Anjula; Bolton, Scott S; Kendig, Arthur C
title: An Unusual Presentation of COVID-19: Hemorrhagic Pericardial Effusion With Tamponade Physiology
date: 2021-02-19
journal: Cureus
DOI: 10.7759/cureus.13438
sha: 613edff08322eb52b91b6a089b1fe5b91a5afa6f
doc_id: 908169
cord_uid: l0rhu9nf

A 44-year-old woman with a history of factor V Leiden deficiency and recurrent pulmonary emboli was diagnosed with coronavirus disease 2019 (COVID-19) three weeks prior presented to her local ED with severe chest pain. She was found to have a large hemorrhagic pericardial effusion by cardiac MRI with echocardiographic signs of tamponade. She underwent the creation of a pericardial window and was treated with colchicine with improvement in symptoms.

Given the overwhelming amount of information being published surrounding the various clinical manifestations seen in patients suffering from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus and coronavirus disease 2019 (COVID-19), few case reports exist defining the pericardial manifestations. Here, we present a case describing a middle-aged female that was found to have a hemorrhagic pericardial effusion, thought to be a late sequela of her previously asymptomatic COVID-19 infection.

A 44-year-old Caucasian female nurse with a history of factor V Leiden deficiency, recurrent pulmonary emboli on chronic warfarin therapy, and hypothyroidism presented to her local emergency department with severe, substernal, and positional chest pain (worse when supine) that radiated to her left shoulder and jaw. She reported COVID-19 positive testing three weeks prior to the presentation including a two-week selfisolation period after her diagnosis. She denied a history of shortness of breath, fever, myalgias, GI complaints, or any other concerning symptoms for COVID-19 infection. Thus, she assumed her result was a false positive. Her local electrocardiogram (EKG) was negative for acute ST-T changes and a CT angiogram was negative for pulmonary emboli or pericardial effusion ( Figure 1 ). She was transferred to our facility for further evaluation of non-ST elevation myocardial infarction (NSTEMI) after a mild troponin elevation was noted (0.4 ng/mL). On admission, her EKG revealed borderline (but not diagnostic) diffuse ST elevation, PR interval depression in leads II, III, aVF, and mild elevation of the PR interval in aVR. A chest x-ray was negative for any acute cardiopulmonary process. Pertinent laboratories included a white blood cell count of Figure 2 ). An echocardiogram demonstrated a large pericardial effusion with right ventricular (RV) diastolic invagination consistent with tamponade. 

There are few cases in the literature describing cardiac manifestations of COVID-19 and fewer isolated cases such as this describing the development of pericarditis and pericardial effusions in COVID-19 infected patients. At this point, there are no reported case reports describing patients presenting with chest pain as the sole complaint this far removed from initial positive testing [1] [2] [3] [4] [5] . Given our patient had a positive COVID-19 test three weeks prior to her presentation (with a two-week isolation period), it is a reasonable conclusion that her hemorrhagic pericardial effusion is related to COVID-19, and thus this is a previously unknown late manifestation of COVID-19 infection. There is an uncertainty that her COVID-19 infection completely explains the hemorrhagic pericardial effusion given her elevated INR on admission. However, a mildly supratherapeutic INR of 3.16 alone resulting in spontaneous hemorrhagic pericarditis would be unlikely. It is more likely that in the setting of COVID-19 pericarditis, anticoagulation may have potentiated the hemorrhagic response. Although the pathophysiology is not completely understood, current literature attributes the development of hemorrhagic pericarditis in COVID-19 patients to the systemic inflammatory response and subsequent cytotoxic and immune-mediated effects related to SARS-COV-2 [3] . Widely available validated testing to assess for COVID-19 infection in pericardial fluid does not exist, thus the fluid from our patient was not able to be tested for confirmation of the presumptive diagnosis [3] . The development of further testing for the detection of COVID-19 in a pericardial fluid is necessary. In terms of management, there are currently no published guidelines for the management of hemorrhagic pericarditis secondary to presumed COVID-19 infection. In the few other reported cases in the literature, patients were treated with colchicine, hydroxychloroquine, steroids, and antivirals. As stated above, we started our patient on colchicine and saw a fairly rapid positive clinical response, with improvement in her symptoms within less than 24 hours. Classically, nonsteroidal anti-inflammatory drugs (NSAIDs) plus colchicine or corticosteroids plus colchicine are used to treat pericarditis [6] . However, given her supratherapeutic INR, NSAIDs were contraindicated. Future studies are needed to determine a standard treatment regimen and the pros/cons of various treatment options.

Acute pericarditis due to COVID-19 infection: an underdiagnosed disease

Cardiac tamponade secondary to COVID-19

Acute effusive pericarditis: a late complication of COVID-19 . Cureus

A case of hemorrhagic cardiac tamponade in a patient with COVID-19 infection

Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19

Etiology of pericardial disease

As COVID-19 positive patients are evaluated, it is important to continually consider the extrapulmonary manifestations of this infection, even in the absence of additional symptoms. Hemorrhagic pericardial effusion with subsequent cardiac tamponade must be considered as a potentially lethal late manifestation of COVID-19 infection. To our knowledge, this is only the second reported case of hemorrhagic pericardial effusion with tamponade physiology secondary to COVID-19 infection reported.

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.